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Abstract: This paper displays the potential of an in-line PAT system for early phase product
development during pharmaceutical continuous manufacturing following a Quality by Design
(QbD) framework. Hot melt extrusion (HME) is used as continuous manufacturing process and
UV–Vis spectroscopy as an in-line monitoring system. A sequential design of experiments (DoE)
(screening, optimisation and verification) was used to gain process understanding for the manufacture
of piroxicam (PRX)/Kollidon® VA64 amorphous solid dispersions. The influence of die temperature,
screw speed, solid feed rate and PRX concentration on the critical quality attributes (CQAs)
absorbance and lightness of color (L*) of the extrudates was investigated using multivariate tools.
Statistical analysis results show interaction effects between concentration and temperature on
absorbance and L* values. Solid feed rate has a significant effect on absorbance only and screw
speed showed least impact on both responses for the screening design. The optimum HME process
conditions were confirmed by 4 independent studies to be 20% w/w of PRX, temperature 140 ◦C,
screw speed 200 rpm and feed rate 6 g/min. The in-line UV-Vis system was used to assess the
solubility of PRX in Kollidon® VA64 by measuring absorbance and L* values from 230 to 700 nm.
Oversaturation was observed for PRX concentrations higher than 20% w/w. Oversaturation can
be readily identified as it causes scattering in the visible range. This is observed by a shift of the
baseline in the visible part of the spectrum. Extrudate samples were analyzed for degradation
using off-line High-Performance Liquid Chromatography (HPLC) standard methods. Results from
off-line experiments using differential scanning calorimetry (DSC), and X-ray diffraction (XRD) are
also presented.
Keywords: hot melt extrusion (HME); Quality by Design; in-line UV-Vis spectroscopy;
Process Analytical Technology (PAT); continuous manufacturing; piroxicam; Kollidon® VA64
1. Introduction
The research presented here adopts and evaluates the sequential experimental design
methodology using in-line monitoring system based on UV-Vis spectroscopy for early phase
product development. In-line sampling is the method of choice for FDA-conforming Process Analytical
Technology (PAT) standards. Sampling takes place directly in the process stream and the measurement
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is performed in real-time. So far, optical spectroscopy has shown to be a suitable in-line technique
for hot melt extrusion (HME). The techniques allow non-invasive sampling without interrupting
continuous processing [1].
Pharmaceutical HME as a continuous manufacturing (CM) system deserves considerable attention.
In the last 10 years, nearly 400 research papers or reviews have been published on CM of pharmaceutical
hot melt extrusion (HME) processes, compared to only 60 between 1997 and 2007. Acceptance of
continuous manufacturing in the regulatory world helps to pave the way for CM [2]. In July 2015,
the U.S. Food and Drug Administration (FDA) approved the use of CM in Vertex’s new cystic fibrosis
drug Orkambi® (lumacaftor, ivacaftor) [3]. In April 2016, Janssen Supply Chain (JSC), a division of
Johnson & Johnson (J&J), received the first approval to switch from batch to continuous processing for
the HIV-1 treatment Prezista® (darunavir) [4].
Pharmaceutical HME process can improve the bioavailability of poorly water-soluble drugs by
the formation of solid solutions or solid dispersions [5–7]. Recently, AstraZeneca commercialized
HME-based tablets Lynparza® (olaparib) for breast and ovarian cancer [8]. It allows embedding of
active pharmaceutical ingredients (API) in polymer matrices under operating parameters that can be
easily adapted to serve a particular application.
Development phase works towards understanding the parameters that influence the quality
of the products. The advantages of a better knowledge of the underlying processes are a higher
predictability of the outcome, meaning a lower risk of failure and an improved quality assurance.
The International Conference on Harmonization, ICH Q8 [9] defines this as the Quality-by-Design
(QbD) approach: “A systematic approach to development that begins with predefined objectives
and emphasizes product and process understanding and process control, based on sound science
and quality risk management.” In practice, a QbD approach in HME means implementing predictive
and/or statistical models that describe the molecular interactions of API and polymers, their miscibility
and the API solubility in the polymer, as well as their physical and chemical stability.
During pharmaceutical HME, API solubility, crystallinity, stability and content uniformity in the
polymer mixture are examples of the potentially critical quality attributes (CQAs) that might need to
be monitored and controlled [10]
Near infrared (NIR), mid-range infrared (MIR) and Raman spectroscopy are commonly
used PAT systems. Most studies and many reviews published deal with NIR and Raman
spectroscopy [11–17]. However, apart from being costly, the techniques are demanding considering
their performance and interpretation. Moreover, they usually lack sensitivity. Meaningful results
depend on how well the process is understood and the use of multivariate data analysis tools.
Because of the complex setup and interpretation, it may be quite time-consuming to gain
reproducible results.
In contrast, UV-Vis tends to be simple and fast both to set up and to interpret. The short integration
time in the millisecond-range delivers rapid results with high sensitivity. UV-Vis therefore is an
interesting tool for optimizing an extrusion process. Real-time monitoring with fast results makes it
easy to identify and change parameters immediately, thus saving time in testing the critical quality
parameters and reproducibility of the results.
Conveniently, many API show a pronounced absorption in the UV spectrum, between 230–380 nm.
Many exclusively or additionally show absorption in the visible part of the spectrum, (380–780 nm) so
this wavelength range should also be considered for extrudate characterization, which is shown in
this study. Although the chemical information delivered is less specific than NIR and Raman, UV-Vis
holds high potential for early phase product development and monitoring manufacturing processes.
However, only few studies have been published on the matter [18–20], quite often investigating
dissolution processes in combination with vibrational spectroscopy [21–25].
In this work, UV-Vis spectroscopy alone is used as in-line monitoring system for early phase
product development to look at the formation of amorphous solid dispersions of API-polymer
as intermediate product to the final tablet formulation. Differential scanning calorimetry (DSC),
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X-ray diffraction (XRD) and High-Performance Liquid Chromatography (HPLC) are used as
off-line characterisation techniques. A qualitative and quantitative evaluation of the extrudates
allow rapid statements on API-polymer: color, appearance and solubility threshold limit or
oversaturation conditions. A simple way to evaluate these parameters is to measure the changes
in absorbance, e.g., at a fixed wavelength, and to calculate lightness (L*) from the spectra.
The results presented here focus at early development phase. The systematic approach started
from identifying a quality target product profile (QTPP) followed by defining critical process
parameters (CPPs) and critical quality attributes (CQAs) using a risk-based analysis. Design of
experiments (DoE) was based on the outcomes of the risk analysis and results and meaningful
conclusions could be reached in no more than one week of experimentation. The aim of this paper is
to show the potential of in-line UV-Vis monitoring as a system in continuous processing for fast early
phase product development in a very simple, quick and responsive way. The selection of the model
system based on PRX was ideal due to its poor solubility and its absorption characteristics in the UV
and visible ranges.
The objectives of this study are to use: in-line UV-Vis spectroscopy as a fast-working PAT
tool for early phase product development during HME; a systematic approach based on sequential
design of experiments to enhance process understanding, optimize and verify process conditions;
multivariate statistical analysis to quantify the relationship between CPPs and CQAs of the extrudates;
propose a design space for the process and evaluate the extrudates using off-line techniques to confirm
observations made with UV-Vis spectroscopy. Real time data of lightness of color (L*) and absorbance
on the visible region were used to identify solubility threshold limit. Oversaturation can be readily
identified as it causes scattering in the visible region and a sharp change on the absorbance and L*
values is observed. Off-line characterization (HPLC, DSC and XRD) was used to support and validate
the in-line measurements.
2. Materials and Methods
A schematic diagram of the pharmaceutical manufacturing process (from powders to tablets)
used in this study is shown in Figure 1. For the extrusion experiments, API piroxicam
(Medex Ltd., Rugby, UK), a poorly water-soluble, non-steroidal anti-inflammatory drug (NSAID),
and poly(vinylpyrrolidone-vinylacetate) copolymer (Kollidon® VA64, BASF, Ludwigshafen, Germany)
were used as a model system. The selection of the polymer was based on its physical stability (viscosity,
miscibility, solubility) and interactions with the API (dipole intermolecular forces, hydrogen bonding).
Kollidon® VA64 has a glass transition temperature close to 100 ◦C and degradation temperature close
to 230 ◦C. The nature of Kollidon® VA 64 as a matrix forming polymer in HME has been previously
studied by researchers to some extent [26].
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The main physicochemical properties of Piroxicam (PRX) include [27]: white crystalline solid;
four known crystal forms: anhydrate (AH) I, II and III and monohydrate (MH); solubility in
water at 22 ◦C: 23 mg/L; melting temperature (Tm): 198–200 ◦C; glass transition temperature (Tg):
61 ◦C; crystallization temperature (Tcr): 60 ◦C and 83 ◦C; relative molar mass: 331.35; logP: 3.1
(P = partition coefficient).
The proposed QTPP is for an immediate release solid dosage form (tablet) with a dose of 20 mg
of PRX for oral administration [10]. Batches of 250 g API/polymer mixture were blended for 10 min
using a tubular mixer. The powder mixture was fed into the extruder using a single screw hopper
(Brabender FlexWall®, Duisburg, Germany). The solid feed rate was varied from 4–8 g/min (screening
design, DoE1).
2.1. Hot Melt Extrusion Experiments
Figure 2 shows the extruder Leistritz Nano16 (Somerville, NJ, USA) with co-rotating twin screws.
The barrel temperature zones 1 to 3 were set to 120 ◦C, 130 ◦C and 140 ◦C, respectively. The powder
feed zone was kept at room temperature. The die temperature, zone 4, was one of the critical process
parameters investigated and the values varied from 130–170 ◦C (DoEs 1&2). The screw elements
were conveying (GF-A3-20-30, GF-A3-15-30 and GF-A3-10-30) and kneading (KB 7-3-15-30 F and KB
7-3-15-60 F). The configuration of the screw shaft is shown in Figure 2d.
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2.2. Risk Assessment and Design Intent
A preliminary risk assessment was carried out for the HME process using the Ishikawa diagram
tool [10]. The die temperature, screw speed and solid feed rate were considered as potentially CPPs.
The concentration of PRX in the polymer blend was also considered as formulation critical factor that
could affect the CQAs solubility threshold limit or oversaturation and appearance of the extrudate.
For the screening design (DoE1, fractional factorial), ten samples were produced (including two
centre points) using the four factors: temperature (150–170 ◦C), screw speed (100–300 rpm), solid feed
rate (4–8 g/min) and API concentration (15–35% w/w).
For the optimization design (DoE2, central composite design), only two factors were considered:
temperature (130–150 ◦C) and API concentration (20–30% w/w). Eleven samples were produced
including three centre points. The prediction profiler results from the statistical model
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(JMP Pro software, SAS Institute, Cary, NC, USA) [28] were used to determine optimum operational
conditions that were then verified in the laboratory (verification studies).
2.3. In-Line Measurements—UV-Vis
For the in-line measurement, the UV-Vis spectrophotometer Inspectro X from ColVisTec, Berlin,
Germany, was coupled to the extruder die. The measurement was conducted with two probes
(TPMP, ColVisTec, Berlin, Germany) in transmission mode, using a range of 230 to 700 nm and a
sampling rate of 0.5 Hz. The UV-Vis probe has a sapphire window (self-cleaning by material flow) with
separable fibre optics for easy calibration. Broad band Xenon flash lamp are used for illumination with
fibre length of 5 m. The calibration of the spectrophotometer was performed using the pure polymer,
Kollidon® VA64 as a blank reference.
2.4. Off-Line Measurements—Differential Scanning Calorimetry (DSC), X-Ray Diffraction (XRD) and
High-Performance Liquid Chromatography (HPLC)
Thermal analysis, differential scanning calorimetry (DSC) was performed using Perkin-Elmer
Jade (Shelton, Connecticut, USA) under N2 atmosphere and heating rate of 20 ◦C/min. Thermal effects
were evaluated using Pyris software.
X-ray diffraction (XRD) was performed using the D2 Phaser X-ray diffractometer (Bruker,
Karlsruhe, Germany). The diffraction profile was measured from 5–40◦ using 2 increments of 0.006.
The samples were set to rotate 15 times per minute.
High-Performance Liquid Chromatography (HPLC) was performed on Agilent 1100
(Agilent Technologies, Stockport, UK). The system consists of: a quaternary pump model G1311A,
a degasser model G1379A, a column oven model G1316A, a photodiode array detector model G1315B
and an autosampler model G1313A. The software Agilent ChemStation Plus (2002) (Agilent, Frankfurt,
Germany) was used to control the system and collect data. Chromatographic separations were carried
out using a C18 column, Kinetex (250 mm × 4.6 mm, 5 µm) manufactured by Phenomenex (California,
USA) at 37 ◦C, using isocratic mobile phase composed by 45% of methanol and 55% of buffer (citric acid
and dibasic sodium phosphate) with flow rate of 1.2 mL min−1.
The method was based on British Pharmacopeia (BP) and United States Pharmacopeia (USP)
assays for sample preparation and chromatographic conditions [29,30]. The wavelengths adopted
for the BP and USP methods are 242 nm and 254 nm respectively. The UV absorption characteristics
of piroxicam, however, allow wavelengths in the range 240 to 400 nm to be used [31–33]. The detection
method applied for the HME samples considered wavelengths between 330 and 360 nm.
3. Results and Analysis
3.1. Sequential Design of Experiments
An essential part of early product development is to have a good understanding of the selected
manufacture process, in this case HME and to understand potential failure modes. The first part of this
work (10 experiments) was to find the acceptable HME process conditions to produce amorphous solid
dispersions of PRX/Kollidon® VA64. Acceptance criteria for “pass” or “failure” were based on the
measurements of absorbance and L* of the samples. The second study (11 experiments) was used to
optimize the settings. Using this sequential approach, it was possible to suggest an optimum operating
condition with only 21 experiments. The results are presented below.
3.1.1. Screening Design
Exemplary results shown in Table 1 and Figure 1 clearly indicate that the ranges used for
temperature and concentration for the screening design (DoE1) were beyond the “edge of failure” of
the acceptable process conditions. A rapid visualization of the products could be done by considering
e.g., appearance and color as “pass” or “fail”. The criteria used for “pass” or “fail” were: transparent
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uniform yellow samples (“pass”) and dark yellowish/brownish/reddish opaque samples suggesting
oversaturation or degradation and/or the presence of bubbles (“fail”).
Table 1. DoE1 Screening study with appearance pass/fail outcome.
Run
Number
API
Concentration
% w/w
Die
Temperature
◦C
Screw
Speed
rpm
Solid Feed
Rate g/min L* %
Abs at
680 nm
Extrudate
Appearance
Extrudate
Colour
Extrudate
Pass/Fail
1 15 150 100 4 96.62 0.01 transparent yellow pass
2 15 150 300 8 60.18 0.43 opaque orange fail
3 15 170 100 8 48.91 0.50 opaque orange fail
4 15 170 300 4 65.14 0.69 opaque dark red fail
5 35 150 300 4 10.07 0.86 opaque orange fail
6 35 150 100 8 49.46 1.86 opaque very dark red fail
7 35 170 300 8 53.59 0.55 opaque orange fail
8 35 170 100 4 40.02 0.49 opaque red fail
9 25 160 200 6 54.23 0.57 opaque dark orange fail
10 25 160 200 6 55.38 0.55 opaque dark orange fail
Figure 3a absorbance vs. wavelength spectra for samples produced at (a) 150 ◦C and (b) 170 ◦C
(DoE1, runs 1–8) shows the absorbance spectra of four samples of DoE1 (runs 1, 2, 5 and 6),
produced at 150 ◦C. At this temperature, the only sample that appeared to score “pass” for the selected
CQAs was run 1 (15% w/w API, 100 rpm screw speed and 4 g/min feed rate). It is not surprising that
run 6 shows the highest values of absorbance due to its very dark-red color and opaque appearance.
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r s 1–8).
Figure 3b shows the four samples (3, 4, 7 and 8) produced at 170 ◦C. It is evident that for high
concentrations (35% w/w) at 170 ◦C the second absorbance peak is shifted to higher wavelength
values (380 to 440 nm) indicating possible different molecular interaction between API/polymer and
therefore different phase structures or morphologies. At 170 ◦C, all extrudates failed. The visible part
of the spectra of all “failed” extrudates showed a significant shift to higher absorbance at wavelengths
>590 nm.
The in-line UV-Vis instrument measures absorbance and color as a function of wavelength.
Numeric color values can be calculated from the spectral transmission measurements across the visible
wavelength range 380 to 780 nm; the CIELAB color specification system based on L*a*b*-values
describes color differences as seen by the human eye. L* or “lightness” is a color parameter that
ranges from black (L* = 0) to diffuse white (L* = 100), b* describes color changes from yellow
to blue, and a* from red to green [34]. The statistical analysis of DoE1 was done considering L*
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and absorbance (at 680 nm) values as responses that represent appearance and solubility threshold
limit (oversaturation) as CQAs. The selection of the absorbance at a fixed wavelength was arbitrary,
but it was important to select a value in the visible range where low variability was observed
(the plateau region), so a simple comparison between samples could be made.
Statistical analysis of response L* yields a linear model with an F Ratio (signal to noise) of 210.83
(Table 2). The adjusted R2 value indicates the model explains 99.76% of the variability. Concentration
and screw speed were shown to be statistically significant, as were the concentration-solid feed rate
interaction and the concentration-temperature interaction. The main effects for temperature and solid
feed rate were included in the model because they are involved in statistically significant interactions
with concentration.
Table 2. Analysis of variance for response L* (DoE1).
Source DF Sum of Squares Mean Square F ratio
Model 6 4138.7755 689.796 210.8323
Error 3 9.8153 3.272 Prob > F
C. Total 9 4148.5908 0.0005*
Summary of Fit
RSquare 0.997634
RSquare Adj 0.992902
Root Mean Square Error 1.808805
Mean of Response 53.36
Observations 10
Sorted Parameter Estimates
Term Estimate Std Error t Ratio Prob > |t |
Concentration (% w/w) (15,35) −14.71375 0.639509 −23.01
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Statistical analysis of response Absorbance (Abs) at 680 nm yields a model with an F Ratio
(signal to noise) of 1276.3 (Table 3). The adjusted R2 value indicates the model explains 99.99% of
the variability. Note that if only linear terms were inclu ed, the the sig al to noise ratio drops to
less than 5 and the adjusted R2 value indicates the model explains less than 55% of the variability.
The inclusion of two centre points in the design allows curvature of one of the factors to be estimated.
By assigning this to the most important main effect (concentration) the model fits are much improved.
However, in this design, the concentration quadratic term is aliased with the quadratic terms of the
other factors, hence a c ntral composite design (DoE2 Optimization design) was required to resolve
this ambiguity of curvature assignment.
Figure 4 shows the prediction profiler plots (JMP software) [28] for the four factors (screw speed,
temperature, solid feed rate and concentration) and two responses (L* and Abs at 680 nm).
Concentration, temperature, screw spee and solid feed r te are plotted against t changes of
L* and Abs at 680 nm in DoE1 setting. The success criteria for the Abs at 680 nm and L* are to achi ve
minimum (close to zero e.g., <0.1) and maximum (close to 100 e.g., <90) values, respectively.
Concentration was the predominant critical parameter for both responses. The prediction profilers
are shown for different settings of concentration in order to show the impact of the interaction
terms. When the co centration is lower (Figure 4a) the t mperature has little effect on Abs t 680
nm. When the conc ntr tion effect is higher (Figure 4b), temperature has an inverse impact on Abs
at 680 nm. Close to saturation, (in this case for concentrations >20% w/w) temperature becomes an
important parameter. Solubility tends to increase with temperature and the responses absorbance at 680
nm and L* are expected to decrease and increase respectively as the temperature increases. Solid feed
rate has a significant effect on absorbance at 680 m nly, an screw speed showed least impac on both
parameters for these experiments. As discussed earlier, the initial ranges used for the factors studied
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in DoE1 were defined based on the physical chemical properties of the API and polymer. This initial
design (screening) resulted in most samples appearing burnt, i.e., possibly degraded. HPLC results
are shown in Section 3.3.3. Consequently, these conditions were beyond the “edge of failure” for the
process and not to be used. A new design was proposed to identify the operating space.
Table 3. Analysis of variance for response Abs at 680 nm (DoE1).
Source DF Sum of Squares Mean Square F ratio
Model 8 2.0420900 0.255261 1276.306
Error 1 0.0002000 0.000200 Prob > F
C. Total 9 2.0422900 0.0216*
Summary of Fit
RSquare 0.999902
RSquare Adj 0.999119
Root Mean Square Error 0.014142
Mean of Response 0.651
Observations 10
Sorted Parameter Estimates
Term Estimate Std Error t Ratio Prob > |t |
Concentration (% w/w) * Temperature (◦C) −0.30375 0.005 −60.75
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3.1.2. Optimization Design
New ranges of temperature and concentration were investigated for the optimization study of the
process conditions. Table 4 shows the runs for DoE2, central composite design.
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Table 4. Parameters and responses for DoE2, central composite design.
Run Number API Concentration% w/w
Die Temperature
◦C
Screw Speed
rpm
Solid Feed
Rate g/min L* %
Abs at
680 nm
Extrudate
Appearance Extrudate Colour
Extrudate
Pass/Fail
1 20 130 200 6 94.58 0.034 transparent uniform yellow pass
2 20 140 200 6 94.69 0.035 transparent uniform yellow pass
3 20 150 200 6 94.11 0.039 transparent uniform yellow pass
4 25 130 200 6 68.05 0.395 opaque yellowish fail
5 25 140 200 6 87.08 0.126 opaque yellowish fail
6 25 140 200 6 87.44 0.133 opaque yellowish fail
7 25 140 200 6 87.51 0.131 opaque yellowish fail
8 25 150 200 6 92.62 0.054 opaque yellowish fail
9 30 130 200 6 39.77 0.930 opaque yellowish fail
10 30 140 200 6 55.18 0.612 opaque yellowish fail
11 30 150 200 6 78.29 0.239 opaque yellowish fail
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Statistical analysis of response L* yields a model with an F Ratio (signal to noise) of
61.5 (Table 5). The adjusted R2 value indicates the model explains 96.03% of the variability.
Concentration, temperature and the concentration-temperature interaction were shown to be
statistically significant. The concentration quadratic term is also significant.
Table 5. Analysis of variance for response L* (DoE2).
Source DF Sum of Squares Mean Square F ratio
Model 4 3249.5224 812.381 61.5001
Error 6 79.2566 13.209 Prob > F
C. Total 10 3328.7790 <.0001*
Summary of Fit
RSquare 0.97619
RSquare Adj 0.960317
Root Mean Square Error 3.634478
Mean of Response 79.93818
Observations 11
Sorted Parameter Estimates
Term Estimate Std Error t Ratio Prob> |t |
Concentration (% w/w) (20,30) −18.35667 1.483769 −12.37
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<.0001*
Temperature (◦C) (130,150) 10.436667 1.483769 7.03 0.0004*
Concentration (% w/w) * Temperature (◦C) 9.7475 1.817239 5.36 0.0017*
Concentration (% w/w) * Concentration (% w/w) −8.436667 2.200786 −3.83 0.0086*
Statistical analysis of response Abs at 680 nm yields a model with an F Ratio (signal to noise)
of 109.6 (Table 6). The adjusted R2 value indicates the model explains 97.75% of the variability.
Concentration, temperature and the concentration-temperature interaction were shown to be
statistically significant. The concentration quadratic term is also significant.
Figure 5 shows the prediction profiler and interaction effects for DoE2. Curvature behaviour was
observed for concentration. As expected, there is a strong interaction effect between concentration
and temperature. At low concentrations (Figure 5a), temperature has little effect on both responses;
i.e., L* and absorbance are insensitive to temperature change at 20% w/w. The API is completely
soluble at this concentration, so increasing the temperature has no effect on both responses. At high
concentrations (Figure 5b) there is a strong effect due to temperature. Increasing temperature leads to
an increase of L* and decrease of Abs at 680 nm values, reflecting lower solubility at lower temperatures.
Samples 4–11 have “failed” the criteria for acceptable process conditions due to mainly solubility
issues (oversaturation) or presence of bubbles. The "failed" samples were outside the intended design
space and, hence, potential operating space.
Table 6. Analysis of variance for response Abs at 680 nm (DoE2).
Source DF Sum of Squares Mean Square F ratio
Model 4 0.82234070 0.205585 109.6522
error 6 0.01124930 0.001875 Prob > F
C. Total 10 0.83359000 <.0001*
Summary of Fit
RSquare 0.986505
RSquare Adj 0.977508
Root Mean Square Error 0.0433
Mean of Response 0.248
Observations 11
Sorted Parameter Estimates
Term Estimate Std Error t Ratio Prob > |t |
Concentration (% w/w) (20,30) 0.2788333 0.017677 15.77
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Figure 5. Prediction Pr filers for DoE2 (a) 20 w and (b) 30% w/w concentrations.
Based on the way the spectroscopic system was calibrated, the “lightness” (L*) represents the API
concentration if the API is in solution. If it is not fully dissolved, particles of undissolved API will
scatter the light out of the transmission path, which reduces the intensity (light vs. dark) [35,36].
This non-selective scattering effect is wavelength independent, as particles are larger than the
wavelength of light. The L* value is very sensitive to this effect, making it a very convenient quantitative
tool for immediate visualization of oversaturation—without any need of a full spectral analysis.
An increase of absorbance intensity (e.g., Abs at 680 nm) could be observed as the concentration
changed from 20 to 30% w/w of PRX at 150 ◦C (Figure 6b). Oversaturation led to a significant shift
of the absorbance values that is also influenced by decreasing temperature. For PRX 20% w/w; run 1
T = 130 ◦C; run 2, T = 140 ◦C; run 3, T = 150 ◦C; samples 1, 2, 3 are transparent and yellowish, “passed”.
For samples prepared at 150 ◦C and concentrations 20–30% w/w (Figure 6b runs 3, 8, 11) the
oversaturation with 30% w/w concentration is clearly shown. Absorbance plateau in the visible spectra
range shifts to higher absorbance with increasing API concentration (run 11), indicating higher opacity,
i.e., oversaturation.
Figure 7 clarifies the relationship between the two factors and API solubility. Absorbance at 680 nm
increases with higher concentration and lower temperature, suggesting that solubility increases with
higher concentration until the point of oversaturation. At 20% w/w API, no influence of temperature
on solubility is observed. As expected, with increasing API concentration, (25% to 30% w/w) and
decreasing temperature (150 ◦C to 130 ◦C), an increasingly pronounced absorbance shift is observed,
indicating oversaturation.
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Figure 6. Absorbance spectra for the response surf ign runs (DoE2) (a) API 20% w/w at 130 ◦C
(run 1) 140 ◦C (run 2) and 150 ◦C (run 3); (b) te erat re at 150 ◦C for API concentrations 20% w/w
(run 3), 25% w/w (run 8) and 30% w/w (run 11).
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3.1.3. Process Parameters Verification
If the criteria for success is set that L* must be greater than 90 and Abs at 680 must be less
than 0.1, then the white region in Figure 8 indicates a potential operating space where the samples can
be produced. The red circles indicate the operating conditions investigated in the verification study.
The DoE2 study showed that the potential design space (the white region) was at the edge of the
investigation space (Figure 8). Lowering the temperature from 170 ◦C prevented apparent degradation
of the samples, however, processability at 130 ◦C was difficult due to the high viscosity of the polymer,
causing high torque. For concentrations at 25% w/w or above most samples appeared to be opaque,
indicating oversaturation of API.
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For this reason, the verification runs (Table 7) were carried out between 135 and 140 ◦C at 20%
w/w concentration (small red circles in Figure 8). For further assurance of ruggedness, the verifications
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were run on different days by different operators at different screw speeds (200–300 rpm), keeping the
feed rate constant at 6 g/min and concentration of 20% w/w.
All the verification runs produced light yellow, transparent samples that were acceptable. They
confirmed the conclusions drawn from DoE1 and DoE2. The variability gauge plot for data across all
studies is shown in Figure 9. The samples above the lower limit for L* and below the upper limit for
Abs at 680 nm “passed” the quality criteria for this early development phase.
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Table 7. Process Conditions Verification study.
Run Number API Concentration% w/w
Die
Temperature ◦C
Screw
Speed rpm
Solid Feed
Rate g/min L* % Abs at 680 nm
Extrudate
Appearance
Extrudate
Colour
Extrudate
Pass/Fail Operator
DoE2 Run2 20 140 200 6 94.69 0.035 transparent light yellow pass A
Verification run 1 20 140 200 6 98.58 –0.006 transparent light yellow pass A
Verification run 2 20 135 200 6 95.30 0.016 transparent light yellow pass B
Verification run 3 20 140 300 6 93.90 0.019 transparent light yellow pass B
Verification run 4 20 135 200 6 95.20 0.015 transparent light yellow pass B
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3.2. In-Line UV-Vis Spectral Visualization
The spectra for each DoE set of runs were recorded continuously and are shown as vertical color
bands from left to right in Figure 10a. Each row consists of several 100 to 2000 color strips representing
the sequence of spectra of each DoE run (10 runs for DoE1 and 11 runs for DoE2). The colors represent
the visible part of the spectra, measured in transmission, of the mixture PRX/Kollidon® VA64. Colors as
seen in Figure 10 were calculated from the spectra based on transmission measurements and expressed
as L*, a*, b* values, thus representing colors as seen by the human eye [34]. Conversion to the
RGB color mode adapted the colors to computer screens and for printers. In the last set of spectra,
highlighted as verification experiment, the dark-grey color is from the cleaning polymer material
(opaque). The white color spectra are pure polymer, without PRX. Rapid changes in color from
yellow-grey shows the formation of bubbles within the extruded API/polymer sample. This could be
due to the presence of moisture. The color red/orange and black suggests deterioration of API due to
excess temperature/concentration (DoE1). The light yellowish color suggests optimum operational
condition producing homogenous transparent API/polymer mixture.
The acceptance ranges for temperature, API concentration, screw speed and solid feed rate were
determined with only 21 experiments and 500 g of API in one week. Using a risk-based approach and
UV-Vis as a PAT system, it became quickly clear that, for this system, temperature and concentration
of API are critical to product CQAs (e.g., solubility threshold limit and L* of the extrudate).Pharmaceutics 2018, 10, x FOR PEER REVIEW  15 of 25 
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Figure 10. (a) Visualization of absorbance spectra of all experiments: DoE1, DoE2, verification.
DoE1: ≈2000 spectra collected in 5 h; DoE2: ≈1500 spectra collected in 3 h; Verification: ≈650
spectra collected in 2 h. (b) Representation of samples from each DoE showing color and appearance
of extrudates: (1) DoE1 opaque and very dark red (run 6: API 35% w/w, T = 150 ◦C, 100 rpm,
8 g/min); (2) DoE2 opaque and slightly orange (run 10: API 30% w/w, T = 140 ◦C, 200 rpm,
6 g/min); (V) Verification, transparent light yellow (run: API 20% w/w, T = 140 ◦C, 200 rpm, 6 g/min).
Reproduced with permission from Lundsberg et al., Pharmaceutical Quality by Design: A Practical
Approach; published by Wiley, 2018.
3.3. Off-Line Measurements—DSC, XRD and HPLC
3.3.1. Differential Scanning Calorimetry
The polymorphism of PRX has been discussed by many authors [37–39] and several analytical
techniques (DSC, XRD, FTIR, NIR, Raman, etc.) have been used to characterize the different crystal
forms of PRX [40–43]. DSC result for pure PRX (onset melting temperature, Tm = 202.7 ◦C) is in
good agreement with the results reported by Vrecˇer et al. [38,39] as crystal form I. The glass transition
temperature (Tg) of pure Kollidon® VA64 (101.5 ◦C) is also in agreement with values from literature [26].
Exemplary thermograms for DoE1 runs are shown in Figure 11a, b. Glass transition temperature
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values decreased as the concentration of PRX increased from 15% w/w (Tg = 84.8 ◦C) to 35% w/w
(Tg = 71.6 ◦C).
For HME process temperatures equal or higher than 150 ◦C (DoE1) except Run 1, all samples
had a dark orange/red color suggesting possible degradation, as shown in Figure 10. As mentioned
before, these conditions were beyond the “edge of failure” for the process. However, the knowledge
acquired from these experiments was important to define the next set of experiments (DoE2).
Kogermann et al. [43] have reported that the presence of degradation products [44] can act
as plasticizers, which support the observed decreasing in Tg values. There is a strong interaction effect
between concentration and temperature, as described earlier (Figure 4).
Thermograms of samples with PRX concentrations of 15% w/w (DoE1) and 20% w/w (DoE2 and
verification) confirmed the presence of amorphous PRX in Kollidon® VA64 formulations.Pharmaceutics 2018, 10, x FOR PEER REVIEW  16 of 25 
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Figure 11. DSC heating curves (20 ◦C/min) of pure PRX, pure Kollidon® VA64 as reference and
samples from (a) DoE1 at 150 ◦C; (b) DoE1 at 170 ◦C.
3.3.2. X-ray Diffraction
The diffraction pattern (Figure 12a,b) for pure PRX is in good agreement with previously published
data [38,39,43] as crystal form I. Kollidon® VA64 XRD pattern is characteristic of an amorphous material
with no sharp and intense peaks [45,46]. The XRD patterns for selected runs from DoE1, DoE2 and
verification runs are shown in Figure 12a,b. There was no sign of crystallinity or characteristic peaks at
specific 2θ angles for samples with PRX concentration of 15% w/w, 20% and 25% w/w. This indicated
the formation of an amorphous solid dispersion in those formulations. This data further supports the
DSC data discussed earlier where the active was completely miscible in the melt extrudates up to 20%
w/w in which there was no sign of the characteristic melting peak of PRX.
Samples with PRX concentrations 30% w/w and 35% w/w (e.g., Run 6, DoE1 and Run 10 DoE2
showed to be partially amorphous, exhibiting relatively less intense and more diffused peaks. The 2θ
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angles of the peaks remained unaffected. These changes in peak intensity could be attributed to the
solubility of PRX in the Kollidon® VA 64 matrix, and the unchanged 2θ angles of the peaks indicate
existence of original crystalline form of the drug (form I) as oversaturated crystal phase. In contrast,
samples with 35% w/w of PRX that were processed at 170 ◦C have shown no XRD patterns. This could
be due to either degradation or excess PRX being re-dissolved (DoE1 runs 7 and 8).Pharmaceutics 2018, 10, x FOR PEER REVIEW  17 of 25 
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Figure 12. XRD diffraction patterns of (a) DoE1 runs and (b) DoE2 and verification runs. Pure PRX
and pure Kollidon® VA64 are shown as reference. Note: V = verification.
3.3.3. High-Performance Liquid Chromatography
The concentrations of the HME samples (DoE1, DoE2 and verification runs) were calculated using
330 nm and 360 nm as the selected wavelengths. Table 8 shows sample nominal concentration, average
area, standard deviation, coefficient of variance, measured concentration and relative areas of Peak A
and Peak B. Peak A (pure PRX, retention time 5.3 min) is observed in all standard solutions used for
the calibration curve experiments and all HME samples. The smaller peak (Peak B) which elutes at
2.4 min is not present at 360 nm for pure PRX or blank chromatograms.
It should be noted that the correlation between the relative percent of Peak B does not correlate
particularly well with the appearance of the run samples described earlier in Table 1. This suggests
there may be other impurities present which have not been resolved from the main peak. Further work
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is required to investigate this. However, it is possible to show (Figure 13) that as we progress from the
screening design to the optimization design to the verification run that the level of Peak B drops.
Table 8. Calculation of sample concentrations based on average peak areas at 330 and 360 nm for DoE1
= Screening Design, DoE2 = optimization and V = verification.
DoE SampleLabel
Run Sample
Concentration
(% w/w)
HPLC Sample
Concentration
(mg/mL)
Peak A Average
Area (mAU*s)
at 360 nm
Peak B Average
Area (mAU*s)
at 330 nm
Relative
Area Peak
A (%)
Relative
Area Peak
B (%)
Measured
Concentration
(mg/mL)
DoE1
Run 1 15 0.0374 1822.12 16.5503 98.93 1.07 0.0319
Run 2 15 0.0372 1838.15 21.3744 98.66 1.34 0.0322
Run 3 15 0.0374 1714.94 31.1404 97.90 2.10 0.0300
Run 4 15 0.0374 1440.43 52.8780 95.87 4.13 0.0250
Run 5 35 0.0875 3076.03 32.0652 98.81 1.19 0.0546
Run 6 35 0.0870 4011.21 32.2373 99.09 0.91 0.0716
Run 7 35 0.0868 3546.24 22.8981 99.24 0.76 0.0632
Run 8 35 0.0873 4330.38 48.7399 98.57 1.32 0.0773
Run 9 25 0.0621 2889.15 29.3632 98.82 1.18 0.0513
Run 10 25 0.0623 2897.23 29.6303 98.84 1.16 0.0514
DoE2
Run 2 20 0.0498 2551.42 18.4762 99.25 0.75 0.0451
Run 6 25 0.0625 3484.15 20.3990 98.23 1.77 0.0620
Run 10 30 0.0743 3963.65 21.7395 99.40 0.60 0.0707
Verification Run 1 20 0.0486 2539.20 6.6582 99.70 0.30 0.0449
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Figure 13. Relative ea r i j i s un I for DoE1, DoE2 and verification runs.
A DoE model fitted to the HPLC data (Table 9 and Figure 14) indicates a good model explaining
ca.94% of the variation. Die temperature has the most important impact on the relative area of Peak B.
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As temperature increases, the other factors become more important (i.e., there are interaction effects
between temperature and the other three factors).
Table 9. Analysis of variance for response relative to peak area B (%).
Summary of Fit
RSquare 0.955
RSquare Adj 0.94375
Root Mean Square Error 0.218715
Mean of Response 1.262383
Observations (or Sum Wgts) 41
Analysis of Variance
Source DF Sum of Squares Mean square F ratio
Model 8 32.485939 4.06074 84.8882
Error 32 1.530764 0.04784 Prob > F
C. Total 40 34.016703 <.0001*
Sorted Parameter Estimates
Term Estimate Std Error t Ratio
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3.4. Extrudate Concentration Studies
Five samples with PRX concentrations from 15 to 25% w/w were processed at 140 ◦C, 200 rpm
and 6 g/min. Figure 15a shows the absorbance spectra versus wavelength (nm) for these five samples.
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The observed shift of the baseline was not due to the polymer but to the excess of API (oversaturation)
in samples with concentrations higher than 20% w/w. Undissolved API causes scattering which is
characteristic of a baseline shift in the visible region. Scattering can also be observed if bubbles are
present, but this was not the case for the process conditions used during these experiments. The values
of absorbance at 680 nm and L* as a function of PRX concentration (15–25% w/w) are shown in
Figure 15b.
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The decrease in L* and increase in absorbance values for samples with concentrations above 20%
clearly confirm the solubility limit threshold for this system, which is between 20–23% w/w of PRX.
4. Discussion
The results showed that qualitative and quantitative assessment of the state of the extrusion
process based on observation of raw spectral data is a very useful system during extrusion.
A model example was chosen where the quality of the extrudate is visible by color and appearance
to the naked eye. Both parameters, color and appearance, already belong to visual pharmaceutical
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quality standards, and it is common that the human eye serves as an instrument to judge purity
or identify contamination during a pharmaceutical manufacturing process. However, these visual
methods are highly subjective and do not deliver quantifiable data. An initial investigation of purity
by HPLC identified a potential degradant (peak B) as a potential source of the color. A more rigorous
study to better quantify peak B (e.g., isolation and identification of peak B and estimation of its relative
response factor) is desirable but is outside the scope of this paper.
The qualitative descriptors in the model experiment were a change of color from yellowish
to brown, indicating possible degradation (DoE1), and a change in appearance from transparent
to opaque, indicating oversaturation (DoE2). UV-Vis spectroscopy enabled quantification of color
of the product by calculating L* values. The system was also shown to be robust and reliable
(verification experiments). Only recent developments in spectroscopic equipment made it possible to
also include the visible part of the spectra into quantitative color analyses. As the model has shown,
the UV–part of the spectra also adds valuable information about the impact of API concentration in
the polymer. A follow-on study is aimed to show the potential of UV-Vis for measuring real time API
concentration in the polymer melt during HME processes.
In the model, the underlying effects of visual quality attributes became apparent in the
absorbance spectra. Changes in color were reflected in a change of absorbance, leading to a shift of the
plateau in the visible part of the spectra. It is therefore possible to measure API solubility threshold
limit or oversaturation with UV-Vis. Furthermore, Abs at 680 nm was chosen to evaluate this shift and
the DoE models identified concentration as the predominant critical parameter and temperature as the
second most influential parameter.
From these analyses, we could immediately conclude that operating close to conditions that
are difficult to control increases the risk of unstable results, i.e., temperatures above 150 ◦C and
concentrations higher than 20% w/w. A decrease in lightness (L*) is the result of a lack of dissolution
of API or caused by another effect that scatters light (e.g., bubbles).
UV-Vis might answer the most urgent questions of early phase product development faster and
more reliably. With a good risk assessment and a simple set of experiments, it was possible to find,
very quickly, in a systematic and multivariate way, that concentration and temperature were most
influential parameters that affect color and solubility limit of the API in the polymer during this
HME process.
Moreover, further experiments in direct comparison showed that UV-Vis is far more sensitive than
NIR and Raman when it comes to small and very low API concentrations (to be published). The results
suggest that UV-Vis spectroscopy could grow out of its niche existence.
So far, NIR and Raman spectroscopy are the most common in-line PAT systems to use in a
QbD-approach. NIR spectroscopy is the most popular technology among the modern process
analyzers and has been increasingly used for real-time measurements of critical process parameters and
product critical quality attributes, as this technique allows rapid and non-destructive measurements
without sample preparations [47–49]. However, the complexity of NIR interpretation results from
the overlapping of hydrogen absorbance bands of the different functional groups (–CH, –OH, –NH,
–SH), requiring chemometrical data for interpretation. A strong calibration and validated model form
the basis for a well-predictive NIR measurement model. Raman spectroscopy is used for routine
qualitative and quantitative measurements of both inorganic and organic materials. It is popular for
raw material identification, as it does not require the use of multivariate modelling [50–53].
The results reported here showed that UV-Vis is a robust and rapid PAT system that can be used
to identify the relationship between CPPs and CQAs in HME processes using multivariate approach.
Ideally, in a manufacturing situation, the use of UV-Vis spectra as a monitoring tool should be
validated first. This case study is more representative of early phase product development, where we
had little prior knowledge from the start. We needed to do exploratory work to understand the process
conditions and the failure modes first. By definition we could only perform the off-line HPLC,
DSC and XRD characterization after we had obtained the samples by continuous manufacture
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therefore by necessity, the off-line validation of the UV-Vis spectra as an in-line monitoring tool
occurred subsequently.
5. Conclusions
In-line UV-Vis spectroscopy was used as a fast-working PAT tool for early phase product
development during HME. A systematic approach based on sequential design of experiments was
used to screen, optimize and verify process conditions using multivariate statistical analysis to quantify
the relationship between critical process parameters (CPPs) and critical quality attributes (CQAs).
Real time data of L* and absorbance on the visible region were used to identify solubility threshold
limit or oversaturation of API in the polymer matrix. The optimum ranges for temperature (140 ◦C),
API concentration (20% w/w), screw speed (200 rpm) and solid feed rate (6 g/min) were determined
and a potential design space was proposed for the acceptable process conditions. Temperature and
concentration were found to have strong interaction effects.
Piroxicam was found to be miscible in Kollidon® VA64 up to 20% w/w drug loading. Results from
off-line characterization using DSC, XRD and HPLC supported the in-line UV-Vis results.
In-line UV-Vis spectroscopy might become a useful system for other extrusion applications.
API solubility can be visualized and monitored by measuring absorbance and calculating L*, a*, b*
color values [19,34]. Moreover, many API show a pronounced absorbance in the UV spectrum and/or
in the visible part of the spectrum, making in-line UV-Vis spectroscopy a potentially widespread
system for monitoring quality in pharmaceutical HME processes.
A follow-on study is aimed to show the potential of UV-Vis for measuring API concentration
in the polymer melt and API content uniformity in powder mixtures (HME upstream and
downstream processes).
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